MRD as an endpoint in clinical trials

Peter Hillman, MD, ChB, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use of measurable residual disease (MRD) as an endpoint in clinical trials. MRD allows for compa... Author: VJHemOnc Added: 06/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts